Pricing Log in Create free account
Friday 6 November 2026 Export MDT’s income statement to Excel — free account

Medtronic PLC

MDT Healthcare Medical Devices

Medtronic PLC’s revenue for fiscal 2026 (year ended April 2026) was $36.4 billion, up 8.43% from fiscal 2025.

Revenue
+13.7%
EPS
+42.0%
Free cash flow
+120.9%
Total debt
−1.59%

Quarter to July 2026, against a year earlier

102.14 2.70 −2.58%
Market cap
$134.1B
P/E
25.6×
Fwd P/E
20.8×
Dividend yield
2.74%
F-score
7/9
Altman Z
2.73
Beneish M
−2.58
Dividend safety
61/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Medtronic PLC (MDT) valuation and DCF model

What the price implies · reverse DCF

At $102.14 the price implies free cash flow after share-based pay growing 9.5% a year for ten years.

Free cash flow after share-based pay grew 0.8% a year over the last ten years, −1.1% over the last five. The price asks for more than four times its ten-year rate. The industry’s median company is priced for 12.5%.

In April 2017 the price assumed 10.4% a year; Medtronic PLC went on to grow free cash flow after share-based pay −0.7% a year to FY2026.

Price implies
9.5%
Last 5 years, reported
−1.1%
Last 10 years, reported
0.8%
Industry median implies
12.5%

The headline discounts the last twelve months’ free cash flow after share-based pay at 9.0% for ten years and grows it 2.5% a year after that, the same for every company, so the figure compares across the market (how a reverse DCF works).

The other way round · DCF
The price needs
9.5% a year for ten years
$102.14
today’s price
Its base case
0.8% a year for five years, then 0.5%
$45.04
55.9% below today’s price

Both are growth in free cash flow after share-based pay, discounted at 9.0%, with 2.5% a year after year ten.

Base case on its own ten-year record Medtronic PLC’s own growth, carried forward

Its assumptions

Powerpack lets you start from a scenario and type over any of them.

The base case’s inputs, which Powerpack lets you change
1 · Cash flow to equity
the four quarters to July 2026, from the 10-Q and 10-K filings, before share-based pay

Yearly growth in cash flow. It usually slows as the company matures.

Today’s price implies free cash flow after share-based pay growing 9.5% a year for ten years.

2 · Rates

Cost of equity is the yearly return shareholders require, typically 8–11%. Terminal growth is growth forever after year 10, usually near long-run inflation, 2–3%.

3 · Per share

Diluted shares outstanding. Net debt, under Advanced inputs, is taken off before dividing.

Advanced inputs
Free cash flow Revenue and margin
negative is net cash
new shares the cash flow does not pay for

Against Medtronic PLC’s own cost of capital: risk-free 4.3% + beta 0.57 × equity premium 4.5% = 6.9% cost of equity; weighted, 6.9%.

Use 6.9%
Equity value $58.00b ▼ below market cap $131.52b
Base case value per share $45.04 equity value ÷ 1.29b shares
Current price $102.14 market price per share
Below today’s price 55.9% downside at the base case’s assumptions

How we got there$37.41b 10 years of cash to equity+$39.92b terminal value−$19.33b net debt=$58.00b equity value÷1.29b shares=$45.04 per share

Valuation against its own history

Today’s multiple against its 5- and 10-year averages and the industry median (Medical Devices).

Multiple Current 5Y avg 10Y avg vs 10Y avg Industry median vs industry 10Y range
P/E 25.62× 26.37× 29.65× 14% below 25.58× 0% above
P/FCF 21.81× 21.75× 24.01× 9% below 28.81× 24% below
P/B 2.63× 2.28× 2.45× 7% above 2.48× 6% above
EV/EBITDA 15.74× 15.18× 16.84× 7% below 11.51× 37% above
EV/Sales 4.08× 3.90× 4.42× 8% below 2.72× 50% above
P/E P/FCF P/B EV/EBITDA EV/Sales
23.86×31.76×39.65×47.54×10Y avg 29.65×2018201920202021202220232024202520262026

MDT trades at 25.62× P/E, against a 10-year average of 29.65× (range 21.65×–49.03×). That is cheaper than 78% of the last 9 year-end readings; re-rating to the average implies $118.24 per share.

Every growth rate on this page is the business’s — its cash flow, FFO or dividend — never its share price’s. A discounted-cash-flow model is only as good as its assumptions. Figures from the 10-K and 10-Q filings. Not investment advice.